In Vitro Activity of a New 8-Methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae

1998 ◽  
Vol 42 (4) ◽  
pp. 951-952 ◽  
Author(s):  
Patricia M. Roblin ◽  
Margaret R. Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
In Vitro Activity

ABSTRACT The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae to a new 8-methoxyquinolone, BAY 12-8039, and to ofloxacin, doxycycline, and erythromycin were determined. The activity of BAY 12-8039 was similar to that of ofloxacin, with a MIC at which 90% of the isolates had no inclusions and a minimal chlamydicidal concentration at which 90% of the isolates had no inclusions after passage of 1.0 μg/ml, but this activity was less than those of doxycycline and erythromycin.

scholarly journals In vitro activity of trovafloxacin against Chlamydia pneumoniae.

1997 ◽  
Vol 41 (9) ◽  
pp. 2033-2034 ◽  
Author(s):  
P M Roblin ◽  
A Kutlin ◽  
M R Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Minimal Concentration

The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.

scholarly journals In Vitro Activity of a Novel Diaminopyrimidine Compound, Iclaprim, against Chlamydia trachomatis and C. pneumoniae

2004 ◽  
Vol 48 (5) ◽  
pp. 1885-1886 ◽  
Author(s):  
S. A. Kohlhoff ◽  
P. M. Roblin ◽  
T. Reznik ◽  
S. Hawser ◽  
K. Islam ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Dihydrofolate Reductase ◽  
Reductase Inhibitor ◽  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
Minimal Bactericidal Concentration ◽  
In Vitro Activity

ABSTRACT The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC90 and MBC90) were 0.5 μg/ml, compared to an azithromycin MIC90 and MBC90 of 0.125 μg/ml and levofloxacin MIC90s and MBC90s of 1 μg/ml for C. trachomatis and 0.5 μg/ml for C. pneumoniae.

scholarly journals In Vitro Activity of a New Antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae

2003 ◽  
Vol 47 (4) ◽  
pp. 1447-1448 ◽  
Author(s):  
Patricia M. Roblin ◽  
Margaret R. Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
Peptide Deformylase ◽  
Minimal Bactericidal Concentration ◽  
In Vitro Activity

ABSTRACT The in vitro activity of NVP-PDF386 (VRC4887), a novel new peptide deformylase inhibitor, and those of levofloxacin and clarithromycin were tested against 21 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by NVP-PDF386 for all isolates of C. pneumoniae were 0.008 μg/ml (range, 0.008 to 0.015 μg/ml) compared to 0.25 and 0.06 μg/ml for levofloxacin and clarithromycin, respectively.

scholarly journals In vitro activity of BAY 12-8039, a new fluoroquinolone.

1997 ◽  
Vol 41 (1) ◽  
pp. 101-106 ◽  
Author(s):  
J M Woodcock ◽  
J M Andrews ◽  
F J Boswell ◽  
N P Brenwald ◽  
R Wise
Keyword(s):  
Chlamydia Pneumoniae ◽  
Marked Effect ◽  
Anaerobic Bacteria ◽  
Lethal Effect ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Beta Lactam ◽  
The Family ◽  
Amoxicillin Clavulanate

The in vitro activity of BAY 12-8039, a new fluoroquinolone, was studied in comparison with those of ciprofloxacin, trovafloxacin (CP 99,219), cefpodoxime, and amoxicillin-clavulanate against gram-negative, gram-positive, and anaerobic bacteria. Its activity against mycobacteria and chlamydia was also investigated. BAY 12-8039 was active against members of the family Enterobacteriaceae (MIC at which 90% of strains tested were inhibited [MIC90S] < or = 1 microgram/ml, except for Serratia spp. MIC90 2 microgram/ml), Neisseria spp. (MIC90S, 0.015 microgram/ml), Haemophilus influenzae (MIC90, 0.03 microgram/ml), and Moraxella catarrhalis (MIC90, 0.12 micrgram/ml), and these results were comparable to those obtained for ciprofloxacin and trovafloxacin. Against Pseudomonas aeruginosa, the quinolones were more active than the beta-lactam agents but BAY 12-8039 was less active than ciprofloxacin. Strains of Stenotrophomonas maltophilia were fourfold more susceptible to BAY 12-8039 and trovafloxacin (MIC90S, 2 micrograms/ml) than to ciprofloxacin. BAY 12-8039 was as active as trovafloxacin but more active than ciprofloxacin against Streptococcus pneumoniae (MIC90, 0.25 microgram/ml) and methicillin-susceptible Staphylococcus auerus (MIC90S, 0.12 micrograms/ml). The activity of BAY 12-8039 against methicillin-resistant S. aureus (MIC90, 2 micrograms/ml) was lower than that against methicillin-susceptible strains. BAY 12-8039 was active against anaerobes (MIC90S < or = 2 micrograms/ml), being three- to fourfold more active against Bacteroides fragilis, Prevotella spp., and Clostridium difficile than was ciprofloxacin. Against Mycobacterium tuberculosis, BAY 12-8039 exhibited activity comparable to that of rifampin (MICs < or = 0.5 micrograms/ml). Against Chlamydia trachomatis and Chlamydia pneumoniae BAY 12-8039 was more active (MICs < or = 0.12 microgram/ml) than either ciprofloxacin or erythromycin and exhibited a greater lethal effect than either to these two agents. The protein binding of BAY 12-8039 was determined at 1 and 5 micrograms/ml as 30 and 26.4%, respectively. The presence of human serum (at 20 or 70%) had no marked effect on the in vitro activity of BAY 12-8039.

Sign in / Sign up

Export Citation Format

Share Document